Background Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to
protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid …

Background The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment
for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (…

In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …

Background The safety and immunogenicity of the bivalent omicron-containing mRNA-1273.214
booster vaccine are not known. Methods In this ongoing, phase 2–3 study, we …

Background At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical
trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 …

Omicron Neutralization and mRNA-1273 Boosters Neutralization of the omicron variant was
assessed in serum samples obtained from persons who had received an mRNA-1273 …

Background The incidence of coronavirus disease 2019 (Covid-19) among adolescents
between 12 and 17 years of age was approximately 900 per 100,000 population from April 1 …

Background Interim analyses of the phase 3 KEYNOTE-006 study showed superior overall
and progression-free survival of pembrolizumab versus ipilimumab in patients with advanced …

BACKGROUND: The Diabetes Prevention Program (DPP) found that an intensive lifestyle
intervention can reduce the development of diabetes by more than half in adults with …

Background The safety, reactogenicity, immunogenicity, and efficacy of the mRNA-1273
coronavirus disease 2019 (Covid-19) vaccine in young children are unknown. Methods Part 1 of …